| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Cramer Speculates In Cv Therapeutics
Posted on 06/17/2007 14:19:52 | Link | Post Comment
by Jon C. Ogg
24/7 Wall St.
On tonight's (Friday) Mad Money on CNBC, Jim Cramer had his normal 'Speculation Friday' and talked CV Therapeutics (CVTX) for a speculative biotech in with Acadia (ACAD) and Nastech (NSTK). Cramer said CVTX is a huge battle ground stock that makes small molecule drugs. Last month it had 36% of the float short, but he thinks the bearish case just doesn't hold up. Cramer thinks the stock could explode into the $20's because of earnings, or it could get acquired and go there. Its Ranexa drug for angina is the driver now, but it could get approved as a diabetic treatment down the road. It has a drug up for potential approval next year to detect cardiac disease. Cramer said it could fetch $20.00 to $36.00 per share if it was to be acquired.
Speculators and biotech investors should know that this one does lose money and it is expected to keep losing money: -$2.95 EPS for fiscal 2007 and expected to post -$1.31 in 2008 fiscal EPS.
Continue article at 247WallSt.com
RELATED READING:
- Cramer's Three Biotech Picks, And His Biotech Strategy
- Cramer's Obesity Stock Plays
247WallSt.com is a regular contributor to BioHealth Investor.com
__________________
24/7 Wall St.
On tonight's (Friday) Mad Money on CNBC, Jim Cramer had his normal 'Speculation Friday' and talked CV Therapeutics (CVTX) for a speculative biotech in with Acadia (ACAD) and Nastech (NSTK). Cramer said CVTX is a huge battle ground stock that makes small molecule drugs. Last month it had 36% of the float short, but he thinks the bearish case just doesn't hold up. Cramer thinks the stock could explode into the $20's because of earnings, or it could get acquired and go there. Its Ranexa drug for angina is the driver now, but it could get approved as a diabetic treatment down the road. It has a drug up for potential approval next year to detect cardiac disease. Cramer said it could fetch $20.00 to $36.00 per share if it was to be acquired.
Speculators and biotech investors should know that this one does lose money and it is expected to keep losing money: -$2.95 EPS for fiscal 2007 and expected to post -$1.31 in 2008 fiscal EPS.
Continue article at 247WallSt.com
RELATED READING:
- Cramer's Three Biotech Picks, And His Biotech Strategy
- Cramer's Obesity Stock Plays
247WallSt.com is a regular contributor to BioHealth Investor.com
__________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Tue Jul 15, 2008 08:25AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Mon Jul 14, 2008 02:18AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home